Bortezomib/Daratumumab/Dexamethasone/Thalidomide Regimen

Preferred Label : Bortezomib/Daratumumab/Dexamethasone/Thalidomide Regimen;

NCIt synonyms : VTD Regimen Plus Daratumumab; Bortezomib/Daratumumab/Dexamethasone/Thalidomide; Darzalex-VTD Regimen; Bortezomib-Daratumumab-Dexamethasone-Thalidomide; Bortezomib-Daratumumab-Dexamethasone-Thalidomide Regimen; Bortezomib-Thalidomide-Dexamethasone Plus Daratumumab; Velcade/Thalidomide/Dexamethasone/Darzalex; Bortezomib/Thalidomide/Dexamethasone Plus Daratumumab; Bortezomib/Thalidomide/Dexamethasone Plus Daratumumab Regimen; Darzalex Plus VTD; VTD-Darzalex; VTd-Darzalex;

NCIt related terms : Dara-VTD;

NCIt definition : A regimen consisting of bortezomib, daratumumab, dexamethasone and thalidomide that can be used for the treatment of plasma cell (multiple) myeloma.;

NCI Metathesaurus CUI : CL1664467;

Codes from synonyms : 77167;

Details

Origin ID

C181587;

UMLS CUI

C5557170;

Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
chemotherapy_regimen_has_component
- Bortezomib [NCIt concept]
- Daratumumab [NCIt concept]
- Dexamethasone [NCIt concept]
- Thalidomide [NCIt concept]
concept_is_in_subset
- HemOnc Regimen Terminology [NCIt concept]
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients